You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NHLBI

    Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIDA

    Project Summary Abstract Under this Fast Track proposalwe will develop Fenrockan abuse deterrent transdermal fentanyl patch based on our proprietary co crystal of naltrexoneNTXand its carefully selected conformermethyl furfuralMFFThis NTXMFFco crystalNTX Cohas the desired properties to stay in a crystalline solid form in the patch when applied to skin as intended but to dissociate to deliver NTX w ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Neonatal Abstinence Syndrome Therapy

    SBC: Mu Therapeutics Inc.            Topic: NIDA

    Neonatal Abstinence Syndrome (NAS) has skyrocketed in recent years as a result of the opioid epidemic plaguing this country. Since 2000, the number of babies affected by NAS has increased nearly 5-fold. Every 25 minutes a baby is born suffering from opioid withdrawal, often prematurely with developmental problems and potential long-term adverse effects including cognitive impairment. Approximately ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: CELL MICROSYSTEMS INC            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Rat Germline Gene Editing Products and Services

    SBC: GenomeDesigns Laboratory LLC            Topic: NIDA

    Summary Rat research models are established to investigate a broad spectrum of human health issues significant to most NIH Institutes and are reported in andgt;1.5 million publications listed on NCBI PubMed Central. Direct germline editing products and services generated by this SBIR project will streamline production of the most sophisticated, genetically designed rat models used to study gene, c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Abstract PTI is developing PTI-125-DX, a novel, quantitative blood-based diagnostic candidate for Alzheimerandapos;s disease (AD). A non-invasive and inexpensive AD diagnostic is sorely needed, particularly one with the ability to detect early pathological changes that precede cognitive symptoms. PTI-125-DX measures the ratio of two protein fragments in plasma and is a companion diagnostic/biomark ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pediatric Implantable Low-Shear Pulsatile Blood Pump with Physiologic Sensing and Control

    SBC: WINDMILL CARDIOVASCULAR            Topic: NHLBI

    Project Summary / Abstract The goal of this project is to develop high-level physiological control, improve low-level dynamic piston control, and develop hemodynamic sensing capabilities for the pediatric TORVADTM, a unique ventricular assist system that delivers low-shear, synchronous, pulsatile flow, using controlled piston motion within a torus-shaped pumping chamber. The pediatric TORVAD is in ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government